Home

MICHAEL S WEISS

CIK 1038977 · Executive Vice Chairman · last filed 2026-03-20

MICHAEL S WEISS is an Executive Vice Chairman who has filed 65 SEC Form 4 insider transactions across 9 companies since 2007. The most recent filing, for FBIOP, was dated Mar 20, 2026. Across all open-market trades the lifetime net is −$5.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.37B across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.37B

Companies

9

Total Filings

65

Lifetime Open-Market Net

-$5.57M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
FBIOP Executive Vice Chairman 2,276,562 $18.76 $42.71M $1.25M 10 2026-03-20
TGTX CEO 24,212,300 $54.87 $1.33B -$3.35M 23 2026-01-09
Checkpoint Therapeutics, Inc. (CKPT) Delisted Director 187,007 $4.26 $796.6K $0 9 2025-05-30
MBIO Director 1,060 $0.63 $669 $0 5 2023-07-07
AVENUE THERAPEUTICS, INC. (ATXI) Delisted Director 22 $0.35 $8 $0 1 2018-08-08
FBIO Exec. VC - Strategic Dev. 533,411 $3.39 $1.81M $0 2 2017-01-27
Fortress Biotech, Inc. (CNDO) Delisted Exec. VC - Strategic Dev. 6,938,038 — — $1.61M 3 2014-11-10
KERYX BIOPHARMACEUTICALS INC (KERX) Delisted Chief Executive Officer 1,465,137 — — -$5.08M 6 2010-05-12
XTLB Director — $2.96 — $0 1 2008-11-04

Recent Filings

65 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-03-20 FBIOP Grant (A) +475,424 $0 EDGAR
2026-01-09 TGTX Grant (A) +622,000 $0 EDGAR
2025-11-07 TGTX Gift (G) −4,668,843 $0 EDGAR
2025-05-30 Checkpoint Therapeutics, Inc. (CKPT) Delisted Mixed −124,812 $64.5K EDGAR
2025-01-30 TGTX Grant (A) +750,000 $0 EDGAR
2025-01-03 FBIOP Grant (A) +454,153 $0 EDGAR
2024-12-17 Checkpoint Therapeutics, Inc. (CKPT) Delisted Grant (A) +12,638 $0 EDGAR
2024-05-16 Checkpoint Therapeutics, Inc. (CKPT) Delisted Grant (A) +82,051 $0 EDGAR
2024-01-08 TGTX Grant (A) +1,001,908 $0 EDGAR
2024-01-03 FBIOP Grant (A) +216,465 $0 EDGAR
Showing 1–10 of 65
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.